To our knowledge, the impact of FDFT1 on inhibiting the Warburg effect has not been reported during fasting; thus, our results innovatively validated that FDFT1 is a negative regulator of glucose metabolism through suppressing the AKT-mTOR-HIF1α pathway during fasting in CRC. Here, AKT1 is linked to colorectal carcinoma.